{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:53:07Z","timestamp":1777614787128,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clinthera.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T01:02:18Z","timestamp":1710118938000},"page":"374-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Global Risdiplam Compassionate Use Program for Patients with Type 1 or 2 Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"46","author":[{"given":"Rakesh","family":"Kantaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senam","family":"Beckley-Kartey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Gorni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Montrocher-Ober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Vindevoghel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.02.006_bib0001","series-title":"Swaiman's Pediatric Neurology: Principles and Practice","article-title":"Genetic disorders affecting the motor neuron: spinal muscular atrophy","author":"Darras","year":"2017"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0003","unstructured":"Spinraza (nusinersen) [package insert]. 2020. Available at: https:\/\/www.spinraza.com\/PI. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0004","unstructured":"Zolgensma (onasemnogene abeparvovec-xioi) [package insert]. Available at: https:\/\/www.fda.gov\/media\/126109\/download. 2019. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0005","unstructured":"Evrysdi (risdiplam) [prescribing information]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf. 2020. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mus.27116","article-title":"Early experiences of nusinersen for the treatment of spinal muscular atrophy: results from a large survey of patients and caregivers","volume":"63","author":"Chen","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0008","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0009","unstructured":"Roche Position on Pre-Approval Access to Investigational Medicinal Products [Roche website]. 2020. Available at: https:\/\/assets.cwp.roche.com\/f\/126832\/x\/d4669b7537\/24_position_pre_approval_access_investigational_medicinal_products_reviewed_april_2020.pdf. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cpt.2140","article-title":"Increasing use of compassionate use\/managed access channels to obtain medicines for use in COVID-19","volume":"110","author":"Aliu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0011","unstructured":"US Food and Drug Administration (FDA). Expanded Access. Available at: https:\/\/www.fda.gov\/news-events\/public-health-focus\/expanded-access. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0012","unstructured":"European Medicines Agency (EMA). Compassionate Use. Available at: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compassionate-use#:~:text=Compassionate%20use%20is%20a%20treatment,who%20cannot%20enter%20clinical%20trials. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","article-title":"Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany","volume":"17","author":"Hahn","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0014","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/acn3.51560","article-title":"An expanded access program of risdiplam for patients with type 1 or 2 spinal muscular atrophy","volume":"9","author":"Kwon","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0015","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0016","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0017","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0018","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/ene.15499","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24\u2009months of treatment","volume":"30","author":"Mercuri","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0019","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0021","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use: Guideline on Compassionate Use of Medicinal Products. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-compassionate-use-medicinal-products-pursuant-article-83-regulation-ec-no-726\/2004_en.pdf. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0022","unstructured":"Electronic Code of Federal Regulations (ECFR). National Archives, Code of Federal Regulations, Requirements for All Expanded Access Uses. Available at: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-312\/subpart-I\/section-312.305. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0023","unstructured":"ClinicalTrials.gov. Expanded access program (EAP) for nusinersen in participants with infantile-onset (consistent with type 1) spinal muscular atrophy (SMA). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02865109. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0024","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/JND-190387","article-title":"Implementing a global expanded access program (EAP) for infantile-onset spinal muscular atrophy (type I): understanding the imperative, impact and challenges","volume":"6","author":"Yong","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0026","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.nmd.2017.09.006","article-title":"Expanded access program with nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience","volume":"27","author":"Messina","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0027","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: Expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0028","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of spinal muscular atrophy type 1\u2014results of expanded access programme in Poland","volume":"55","author":"Modrzejewska","year":"2021","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0029","first-page":"A122","article-title":"G299\u2005Nusinersen (Spinraza) is the first drug approved for spinal muscular atrophy (SMA): initial experience in patients with SMA type 1 treated in the expanded access program (EAP)","volume":"103","author":"Scoto","year":"2018","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2022.05.001","article-title":"Safety of onasemnogene abeparvovec for patients with spinal muscular atrophy 8.5 kg or heavier in a global managed access program","volume":"132","author":"Chand","year":"2022","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinthera.2024.02.006_bib0031","unstructured":"The World Bank. Data: World Bank Country and Lending Groups. Available at: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups#:~:text=%EF%BB%BF%EF%BB%BF%20For%20the%20current,those%20with%20a%20GNI%20per. Accessed August 2023."},{"key":"10.1016\/j.clinthera.2024.02.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.0475","article-title":"International country-level trends, factors, and disparities in compassionate use access to unlicensed products for patients with serious medical conditions","volume":"3","author":"Aliu","year":"2022","journal-title":"JAMA Health Forum"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T12:56:35Z","timestamp":1716296195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0149291824000614"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.02.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global Risdiplam Compassionate Use Program for Patients with Type 1 or 2 Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}